Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryCardiologyHeart Pump DevicesSafety Signal

Abiomed Issues Update on Automated Impella Controllers Due to Software Error

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Heart Pump Devices
Asset: Abiomed
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Abiomed

Indication

Cardiology / Heart Pump Devices

Status

Under Review

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Why it matters

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

What changed

Safety Signal

Analysis

A software error may cause the Automated Impella Controller to restart when used with left ventricular Impella devices.

The software error in Abiomed's Automated Impella Controllers poses a significant safety risk, potentially undermining user trust and market position. This situation necessitates close monitoring of regulatory responses and communication strategies to address stakeholder concerns.

Monitor for further updates from Abiomed regarding the resolution of the software issue and any regulatory actions.

Related companies & assets

Assets

  • Abiomed →

Sources & Humanexa intelligence

Source links

  • Abiomed Issues Update on Automated Impella Controllers Due to Software Error ↗

Related Humanexa pages

  • Abiomed Issues Update on Automated Impella Controllers Due to Software Error →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Biogen

Asset

FDA

Indication

Neurology / Depression

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplemental NDA for Zuranolone (ZURZUVAE) by Biogen

The FDA has accepted a supplemental NDA for Zuranolone (ZURZUVAE) submitted by Biogen.

July 5, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Aurobindo Pharma

Asset

Canagliflozin

Indication

Diabetes / SGLT2 Inhibitor

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

Aurobindo Pharma's ANDA for Canagliflozin Receives Approval Status

Aurobindo Pharma's ANDA210386 for Canagliflozin has received an approval status (AP) from the FDA.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.